ClinicalTrials.gg
RecruitingNCT07058155OPTIMALUpdated Oct 22, 2026

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

A Phase 4 interventional study of Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Sleeve Gastrectomy in Liver Cirrhoses, Portal Hypertension Related to Cirrhosis and Severe Obesity, sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by The Cleveland Clinic · Phase 4, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Oct 22, 2026Eligibility revisedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 213 studies in Obesity, Morbid with a site in United States — 28 open to participants now, 36 under way, 1 of them phase 3. Obesity, Morbid · United States.

Planned enrollment
51st of 150
70 · median 39
Started
2025
with 2 others
Phase 4
13 of 213
2 open now
Primary completion
2029-02
later than 31 of 34 live
Registered
210th of 213
by date
Lead sponsor
4 of 213
The Cleveland Clinic

Among the 213 studies in Obesity, Morbid with a site in United States, this one is the 51st largest by planned enrollment of the 150 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 in phase 4, reaches primary completion later than 31 of the 34 other live ones, and was the 210th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

28 of the 213 studies in Obesity, Morbid with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 213 studies in Obesity, Morbid with a site in United States, or all of them as a file.
02

Study summary

Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. CSPH raises the risk of life-threatening events like internal bleeding and liver failure. Unfortunately, treatment options for people who have both cirrhosis and severe obesity are very limited, especially when portal hypertension is present.

This study, called the OPTIMAL Trial, is a randomized clinical trial designed to evaluate whether combining two procedures improves health outcomes in this high-risk population. The first procedure, called TIPS (Transjugular Intrahepatic Portosystemic Shunt), is a minimally invasive treatment that reduces pressure in the liver by creating a pathway for blood to flow more easily. The second procedure is sleeve gastrectomy, a form of metabolic (bariatric) surgery that helps patients lose weight and improve related conditions like diabetes.

The study will compare two groups:

  1. One group will receive TIPS followed by sleeve gastrectomy (TIPS+SG).
  2. The other group will receive medical weight management (standard non-surgical care, including diet, lifestyle changes, and weight loss medications).

All participants will have severe obesity and cirrhosis with CSPH but will not have decompensated liver disease (such as large amounts of fluid in the abdomen, a history of variceal bleeding, or recent liver failure). Eligible participants will be randomly assigned to one of the two groups.

The main goal of the study is to determine whether the combination of TIPS + SG improves quality of life and leads to greater weight loss compared to medical therapy alone. The study will also monitor for any complications from either the procedures or the medical treatment.

Participants will be followed for 6 months after their treatment starts, with periodic assessments of their physical health, liver function, and overall well-being. Some participants may also be followed for a longer period to assess long-term outcomes.

This study hopes to provide high-quality evidence for a novel, stepwise treatment strategy that may help people with obesity and liver disease live longer, healthier lives. If successful, it could change how advanced liver disease and obesity are managed together, especially in patients who currently have few safe and effective options. All study care is provided at Cleveland Clinic, Cleveland, Ohio, USA.

Read the detailed description

Obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) are now among the leading global causes of cirrhosis. Up to one-third of individuals with cirrhosis also have class II or III obesity, which exacerbates portal hypertension, accelerates liver disease progression, and can limit eligibility for liver transplantation. Metabolic (bariatric) surgery is an established treatment that induces sustained weight loss and improves metabolic and hepatic outcomes. However, the presence of clinically significant portal hypertension (CSPH) increases the risks of surgery, including intraoperative bleeding and postoperative hepatic decompensation. Small retrospective studies suggest that placing a transjugular intrahepatic portosystemic shunt (TIPS) before surgery may reduce these risks by decompressing the portal venous system. To date, no prospective randomized trial has evaluated this approach.

The OPTIMAL Trial (Optimizing Portal Hypertension with TIPS and Interval Metabolic Surgery for Advanced Liver Disease) is a single-center, prospective randomized controlled trial designed to determine whether a staged strategy using TIPS followed by sleeve gastrectomy improves health-related quality of life (HRQoL), weight loss, and safety in patients with cirrhosis, severe obesity, and CSPH compared to medical management alone.

The trial will enroll 70 adults aged 18 to 70 years with a body mass index (BMI) between 35 and 70 kg/m², biopsy-proven or elastography-confirmed cirrhosis, and objective evidence of CSPH. Inclusion criteria include Child-Pugh class A or B liver function, MELD 3.0 score \<=15, and platelet count >= 50,000 /µL. Key exclusion criteria include decompensated cirrhosis, defined as moderate-to-large volume ascites, hepatic encephalopathy, or patients undergoing liver transplant evaluation. Patients with a history of variceal hemorrhage or small-volume ascites may still be eligible. Other exclusions include MELD 3.0 > 15, portal vein thrombosis, hepatocellular carcinoma, prior metabolic surgery, pregnancy, active substance use, untreated psychiatric illness, and severe cardiopulmonary disease that would preclude surgery or anesthesia.

After informed consent, participants will be randomized in a 1:1 ratio to one of two arms. The intervention group will undergo TIPS placement, aiming for at least a 50 percent reduction in hepatic venous pressure gradient (HVPG) or a final HVPG less than 12 mmHg, followed by sleeve gastrectomy approximately 4 to 6 weeks later. The control group will receive structured lifestyle counseling and, when clinically indicated, FDA-approved pharmacologic therapies for weight management and diabetes.

Follow-up visits at 1, 3, and 6 months will assess weight, vital signs, adverse events, and MELD 3.0 laboratory values. Liver Doppler ultrasound will be performed in the intervention group to assess TIPS patency per standard of care. Both groups will complete the SF-36 survey to evaluate health-related quality of life. The primary outcome is the change in SF-36 Physical Component Summary (PCS) score from baseline to 6 months. Secondary outcomes include percentage of total body weight loss, incidence of serious liver-related complications such as hepatic encephalopathy, variceal bleeding, and acute-on-chronic liver failure, as well as changes in SF-36 scores at 1 and 3 months. Exploratory outcomes include changes in MELD 3.0 parameters (bilirubin, albumin, INR, sodium, and creatinine); proportion of participants achieving 5% to 25% weight loss; changes in BMI, waist circumference, and body composition; changes in glucose and HbA1c in patients with type 2 diabetes; proportion meeting HbA1c targets (\<6.5% without medications, \<7% overall); and changes in cardiovascular and diabetes medication use.

Following randomization, all patients who receive TIPS or start nonsurgical management will be analyzed based on the intention-to-treat plan. Furthermore, patients who undergo TIPS placement but not sleeve gastrectomy for any reason, such as the development of de novo portal vein thrombosis, development of de novo acute renal failure, or persistent esophageal varices, will not be included in the per-protocol (on treatment) analysis.

This trial will generate the first prospective data evaluating whether a combined approach of portal pressure reduction and metabolic surgery can safely and effectively improve quality of life, metabolic control, and liver-related outcomes in patients with cirrhosis, severe obesity, and CSPH.

03

Conditions studied

  • Liver Cirrhoses
  • Portal Hypertension Related to Cirrhosis
  • Severe Obesity
  • TIPS

Keywords

  • Sleeve Gastrectomy
  • Transjugular Intrahepatic Portosystemic Shunt (TIPS)
  • Bariatric Surgery / Metabolic Surgery
  • Clinically Significant Portal Hypertension (CSPH)
  • Health-Related Quality of Life (HRQOL)
  • SF-36 Questionnaire
  • Weight Loss
  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)
  • Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Randomized Controlled Trial
04

Who can participate

The criteria were revised on the registry on Oct 22, 2026. See what changed

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a candidate for general anesthesia
  2. Is ≥18 and ≤70 years old at the time of signing the
  3. Has a ≥35 and ≤85 kg/m2 at the time of first study visit
  4. Is eligible for metabolic surgery (SG) based on the ASMBS/IFSO 2022 guidelines [39]
  5. Has insurance coverage for metabolic surgery
  6. Patients who are currently receiving or have previously received anti-obesity medicines will be considered for participation
  7. Liver cirrhosis as determined via liver or noninvasive liver disease assessment
  8. CSPH as determined by HVPG of ≥ 10-12 mmHg, presence of esophagogastric varices, moderate-to-severe portal hypertensive gastropathy, dilated portal vein (>13 mm), biphasic or reverse portal vein flow, enlarged paraumbilical veins, splenorenal collaterals, or dilated left and short gastric veins.
  9. Has the ability and willingness to participate in the study, provide informed consent, and agree to any of the arms involved in the study.
  10. Has a negative urine pregnancy test at the first visit and at the randomization visits for women of .
  11. Women of childbearing age must agree to use reliable method of for 2 years.

Exclusion criteria

Exclusion Criteria

  1. Prior bariatric and metabolic surgery of any kind

    • Reversed procedures such as gastric band or intragastric balloon that have been removed at least 3 months prior to the first study visit are allowed.
  2. Prior complex foregut surgery including any esophageal and gastric surgeries, anti-reflux procedures, biliary diversion, and complex trauma surgery
  3. History of solid organ transplant
  4. Severe pulmonary disease defined as \< 50% of predicted value
  5. Significant cardiac or atherosclerotic disease (planned to undergo cardiac, coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)
  6. Severe uncompensated cardiopulmonary disease leading to Class IV or V
  7. \<25% at the time of screening
  8. Myocardial infarction, unstable angina, stroke, heart surgery, coronary stent placement in the past 6 months
  9. Presence of large hiatal hernia (>7 cm)
  10. Presence of erosive esophagitis (LA Grade C and D)
  11. Presence of active Crohn's disease
  12. Psychiatric disorders including (but not limited to) dementia, active psychosis, severe depression requiring 3 or more medications, history of suicide attempts, active alcohol, or substance abuse within the previous 12 months that in the opinion of the investigators could disqualify the patient from metabolic surgery
  13. Pregnancy, the intention of becoming pregnant, or not using adequate measures
  14. Breastfeeding
  15. Diagnosis of within the preceding 1 year, including intra- or extra-hepatic malignancy. This includes known hepatocellular carcinoma or evidence of OPTN-V lesion on imaging (except squamous cell and basal cell cancer of the skin).
  16. Clinical judgment that is less than 2 years
  17. Use of therapy within 3 months prior to signing the consent
  18. Acute pancreatitis \< 90 days before screening
  19. Portal vein thrombosis
  20. Decompensated cirrhosis: moderate-to-large volume ascites, hepatic encephalopathy, or patients undergoing liver transplant evaluation.

    • We will include patients with prior variceal hemorrhage or small volume ascites
  21. Total > 3 mg/dl within 1 month of screening
  22. > 1.7 within 1 month of screening
  23. \<50,000 per microliter within 1 month of screening
  24. Current or history of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to the first study visit.

    • Defined as more than 14 units/week for females (>1 drink per day) and more than 21 units/week for males (>2 drinks per day) on average, where one unit of alcohol is equivalent to a 12-ounce beer, 4-ounce glass of wine, or 1-ounce shot of hard liquor.
  25. Chronic renal insufficiency with estimated (eGFR) below 45 mL/min/1.73 m2 or being on dialysis within 1 month of screening.
  26. Known cases of Acquired Immune Deficiency Syndrome (AIDS)
  27. Unable to understand the risks, benefits, and compliance requirements of study
  28. Lack capacity to give
  29. Plans to move outside the primary location of study (within 3-hour distance of Cleveland) within the next 6 months.
  30. Previous participation in this trial and got randomized to one of the study groups but did not proceed.
  31. Any condition or major illness that, in the investigator's judgment, places the subject at undue risk by participating in the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    TIPS + Sleeve Gastrectomy

    Participants first undergo transjugular intrahepatic portosystemic shunt (TIPS) placement (target HVPG \< 12 mmHg or ≥ 50 % reduction). After portal pressure stabilization-ideally 4-6 weeks, allowed ≤ 6 months-they receive laparoscopic or robotic sleeve gastrectomy. Standard peri- and post-operative care, plus routine lifestyle counseling, are provided.

    Procedure: Transjugular Intrahepatic Portosystemic Shunt (TIPS) · Procedure: Sleeve Gastrectomy · Behavioral: Lifestyle Counseling - Diet & Physical-Activity Program

  • Active comparator
    Best-Option Medical Weight Management

    Participants will follow an individualized, clinician-directed medical weight loss program that includes dietary and physical activity counseling, behavior modification strategies, and best available anti-obesity pharmacotherapy (e.g., GLP-1 receptor agonists, dual incretin agonists, first generation AOMs).

    Drug: Anti-Obesity Pharmacotherapy (Class Effect) · Behavioral: Lifestyle Counseling - Diet & Physical-Activity Program

Interventions

  • ProcedureTransjugular Intrahepatic Portosystemic Shunt (TIPS)

    Fluoroscopically guided placement of a covered stent creating a portosystemic shunt between hepatic and portal veins. Goal: ≥ 50 % HVPG reduction or final HVPG \< 12 mmHg. Conducted 4-6 weeks (≤ 6 months allowed) before bariatric surgery; standard post-TIPS surveillance ultrasound and EGD to confirm patency and variceal resolution.

    Also known as: TIPS

  • ProcedureSleeve Gastrectomy

    Longitudinal resection of \~80 % of stomach via laparoscopic or robotic approach, preserving pylorus. Performed after successful TIPS once portal pressures stabilize (\< 6 months post-TIPS). Standard peri-operative care, micronutrient supplementation, and bariatric follow-up per ASMBS guidelines.

    Also known as: SG

  • DrugGLP-1 MimeticStudies of GLP-1 MimeticGLP-1 Mimetic pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Clinician-selected, evidence-based anti-obesity medications (AOMs) used at the treating provider's discretion. Agents may include incretin-based therapies (e.g., Semaglutide, Tirzepatide) or other FDA-approved AOMs such as Topiramate or Phentermine. Dosing and titration follow standard labeling; no specific drug is mandated. The study assesses the overall class effect of pharmacotherapy rather than any single agent.

    Also known as: GLP-1 receptor agonist, Topiramate, Phentermine, Incretin Mimetics

  • BehavioralLifestyle Counseling - Diet & Physical-Activity Program

    Regular sessions with a registered dietitian or equivalent (in-person or virtual) focusing on adherence to a reduced-calorie diet, structured physical-activity regimen, and behavior-change strategies. Counseling occurs throughout the 6-month study period and is considered standard care for this patient population.

    Also known as: Dietary modification, Exercise counseling, Behavioral weight-loss coaching

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in SF-36 Physical Component Summary (PCS) Score From Baseline to 6 Months

    Difference between baseline and 6-month SF-36 PCS score (0-100 scale; higher values = better physical health-related quality of life). Positive change denotes improvement.

    Time frame: At 6 months after treatment initiation (Day 0 = TIPS placement date or start of medical management).

Secondary outcomes

  1. Percent Total Body-Weight Loss (%TBWL) at 6 Months

    %TBWL = ((baseline weight - 6-month weight) ÷ baseline weight) × 100.

    Time frame: At 6 months after treatment initiation

  2. Incidence of Serious Complication Composite Within 6 Months

    Proportion of participants experiencing ≥ 1 of the following: severe hepatic encephalopathy (requiring hospitalization/intubation/TIPS revision), variceal hemorrhage, acute-on-chronic liver failure, deep intra-abdominal infection, severe sepsis, blood transfusion, pulmonary embolism, initiation of dialysis, or death.

    Time frame: Up to 6 months after treatment initiation

  3. Change in SF-36 Physical Component Score From Baseline to 1 Month

    Differences in SF-36 Physical Component Score at one month versus baseline (higher = better physical health-related quality of life).

    Time frame: Baseline and 1 month

  4. Change in SF-36 Mental Component Score From Baseline to 1 Month.

    Differences in SF-36 Mental Component Score at one month versus baseline (higher = better mental health-related quality of life).

    Time frame: Baseline and 1 month.

  5. Change in SF-36 Physical Component Score From Baseline to 3 Months

    Differences in SF-36 Physical Component Score at three months versus baseline (higher = better physical health-related quality of life).

    Time frame: Baseline and 3 months

  6. Change in SF-36 Mental Component Score From Baseline to 3 Months.

    Differences in SF-36 Mental Component Score at three months versus baseline (higher = better mental health-related quality of life).

    Time frame: Baseline and 3 months.

Other outcomes

  1. Change in HbA1c (%)

    Mean absolute change in glycated hemoglobin (HbA1c, percent) between baseline and each follow-up visit

    Time frame: Baseline and 6 months (Week 24) after treatment initiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Feb 2029, 37 months after the start.

Of 28 phase 4 interventional studies under Obesity, Morbid, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2025
First posted
Jul 10, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Feb 1, 2029
CompletionEst.
Feb 1, 2034
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
5 inclusion criteria edited, 6 added, 5 removed; 10 exclusion criteria edited, 24 added, 15 removed
What changed in the criteria
Inclusion criteria
  • EditedCandidateIs a candidate for general anesthesia.
  • ChangedBefore Age 18-70 years at consent.Now Is ≥18 and ≤70 years old at the time of signing the informed consent
  • EditedHas a BMI ≥35-70 and ≤85 kg/m²m2 at the time of first study visit.
  • ChangedBefore Eligible for sleeve gastrectomy per ASMBS/IFSO 2022 guidelines.Now Is eligible for metabolic surgery (SG) based on the ASMBS/IFSO 2022 guidelines [39]
  • EditedInsuranceHas insurance coverage for metabolic surgery.
  • RemovedCurrent or prior anti-obesity medication use permitted.
  • RemovedLiver cirrhosis confirmed by biopsy or non-invasive assessment.
  • RemovedClinically significant portal hypertension (HVPG ≥ 10 mm Hg, or esophagogastric varices / portal-hypertensive gastropathy, or imaging evidence of collaterals/dilated portal vein).
  • RemovedAble and willing to provide informed consent and comply with study procedures.
  • RemovedWomen of child-bearing potential: negative urine pregnancy test at screening and randomization and agreement to reliable contraception for 2 years.
  • AddedPatients who are currently receiving or have previously received anti-obesity medicines will be considered for participation
  • AddedLiver cirrhosis as determined via liver biopsy or noninvasive liver disease assessment
  • AddedCSPH as determined by HVPG of ≥ 10-12 mmHg, presence of esophagogastric varices, moderate-to-severe portal hypertensive gastropathy, dilated portal vein (>13 mm), biphasic or reverse portal vein flow, enlarged paraumbilical veins, splenorenal collaterals, or dilated left and short gastric veins.
  • AddedHas the ability and willingness to participate in the study, provide informed consent, and agree to any of the arms involved in the study.
  • AddedHas a negative urine pregnancy test at the first visit and at the randomization visits for women of childbearing potential.
  • AddedWomen of childbearing age must agree to use reliable method of contraception for 2 years.
Exclusion criteria
  • RemovedPrior bariatric/metabolic surgery (except removed devices ≥ 3 months earlier).
  • RemovedPrior complex foregut surgery.
  • AddedPrior bariatric and metabolic surgery of any kind
  • AddedReversed procedures such as gastric band or intragastric balloon that have been removed at least 3 months prior to the first study visit are allowed.
  • AddedPrior complex foregut surgery including any esophageal and gastric surgeries, anti-reflux procedures, biliary diversion, and complex trauma surgery
  • EditedHistory of solid- organ transplant.
  • EditedSevere pulmonary disease (defined as FEV1 < 50 % of predicted). value
  • RemovedSignificant cardiac or atherosclerotic disease with planned re-vascularization within 12 months.
  • RemovedASA class IV or V uncompensated cardiopulmonary disease.
  • RemovedLeft-ventricular ejection fraction < 25 % or MI/unstable angina/stroke/heart surgery/coronary stent within 6 months.
  • RemovedHiatal hernia > 7 cm or LA grade C/D erosive esophagitis.
  • AddedSignificant cardiac or atherosclerotic disease (planned to undergo cardiac, coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)
  • AddedSevere uncompensated cardiopulmonary disease leading to American Society of Anesthesiologists Class IV or V
  • AddedLeft ventricular ejection fraction <25% at the time of screening
  • AddedMyocardial infarction, unstable angina, stroke, heart surgery, coronary stent placement in the past 6 months
  • AddedPresence of large hiatal hernia (>7 cm)
  • AddedPresence of erosive esophagitis (LA Grade C and D)
  • EditedActivePresence of active Crohn's disease.
  • RemovedSevere psychiatric illness, dementia, active psychosis, history of suicide attempt, or alcohol/substance abuse within 12 months.
  • RemovedPregnant, breastfeeding, planning pregnancy, or not using adequate contraception.
  • RemovedMalignancy within the prior 12 months (except non-melanoma skin cancer).
  • RemovedLife expectancy < 2 years in investigator's judgment.
  • AddedPsychiatric disorders including (but not limited to) dementia, active psychosis, severe depression requiring 3 or more medications, history of suicide attempts, active alcohol, or substance abuse within the previous 12 months that in the opinion of the investigators could disqualify the patient from metabolic surgery
  • AddedPregnancy, the intention of becoming pregnant, or not using adequate contraceptive measures

…and 25 more changes, on the record history on ClinicalTrials.gov ↗

Oct 22, 2026
Contact
Study contact changed: h•••@ccf.org · •••5022→d•••@ccf.org · •••0045; removed A•••@ccf.org. See the current contact
Oct 22, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Cleveland Clinic Main Campus · Cleveland, United StatesContact h•••@ccf.org · •••5022→D•••@ccf.org · •••0045Contact A•••@ccf.org→none listedContact removed (no phone or email listed)Contact removed (no phone or email listed)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Eligibility 5 inclusion criteria edited, 6 added, 5 removed; 10 exclusion criteria edited, 24 added, 15 removed
    What changed in the criteria
    Inclusion criteria
    • EditedCandidateIs a candidate for general anesthesia.
    • ChangedBefore Age 18-70 years at consent.Now Is ≥18 and ≤70 years old at the time of signing the informed consent
    • EditedHas a BMI ≥35-70 and ≤85 kg/m²m2 at the time of first study visit.
    • ChangedBefore Eligible for sleeve gastrectomy per ASMBS/IFSO 2022 guidelines.Now Is eligible for metabolic surgery (SG) based on the ASMBS/IFSO 2022 guidelines [39]
    • EditedInsuranceHas insurance coverage for metabolic surgery.
    • RemovedCurrent or prior anti-obesity medication use permitted.
    • RemovedLiver cirrhosis confirmed by biopsy or non-invasive assessment.
    • RemovedClinically significant portal hypertension (HVPG ≥ 10 mm Hg, or esophagogastric varices / portal-hypertensive gastropathy, or imaging evidence of collaterals/dilated portal vein).
    • RemovedAble and willing to provide informed consent and comply with study procedures.
    • RemovedWomen of child-bearing potential: negative urine pregnancy test at screening and randomization and agreement to reliable contraception for 2 years.
    • AddedPatients who are currently receiving or have previously received anti-obesity medicines will be considered for participation
    • AddedLiver cirrhosis as determined via liver biopsy or noninvasive liver disease assessment
    • AddedCSPH as determined by HVPG of ≥ 10-12 mmHg, presence of esophagogastric varices, moderate-to-severe portal hypertensive gastropathy, dilated portal vein (>13 mm), biphasic or reverse portal vein flow, enlarged paraumbilical veins, splenorenal collaterals, or dilated left and short gastric veins.
    • AddedHas the ability and willingness to participate in the study, provide informed consent, and agree to any of the arms involved in the study.
    • AddedHas a negative urine pregnancy test at the first visit and at the randomization visits for women of childbearing potential.
    • AddedWomen of childbearing age must agree to use reliable method of contraception for 2 years.
    Exclusion criteria
    • RemovedPrior bariatric/metabolic surgery (except removed devices ≥ 3 months earlier).
    • RemovedPrior complex foregut surgery.
    • AddedPrior bariatric and metabolic surgery of any kind
    • AddedReversed procedures such as gastric band or intragastric balloon that have been removed at least 3 months prior to the first study visit are allowed.
    • AddedPrior complex foregut surgery including any esophageal and gastric surgeries, anti-reflux procedures, biliary diversion, and complex trauma surgery
    • EditedHistory of solid- organ transplant.
    • EditedSevere pulmonary disease (defined as FEV1 < 50 % of predicted). value
    • RemovedSignificant cardiac or atherosclerotic disease with planned re-vascularization within 12 months.
    • RemovedASA class IV or V uncompensated cardiopulmonary disease.
    • RemovedLeft-ventricular ejection fraction < 25 % or MI/unstable angina/stroke/heart surgery/coronary stent within 6 months.
    • RemovedHiatal hernia > 7 cm or LA grade C/D erosive esophagitis.
    • AddedSignificant cardiac or atherosclerotic disease (planned to undergo cardiac, coronary, carotid, or peripheral artery revascularization procedures in the next 12 months)
    • AddedSevere uncompensated cardiopulmonary disease leading to American Society of Anesthesiologists Class IV or V
    • AddedLeft ventricular ejection fraction <25% at the time of screening
    • AddedMyocardial infarction, unstable angina, stroke, heart surgery, coronary stent placement in the past 6 months
    • AddedPresence of large hiatal hernia (>7 cm)
    • AddedPresence of erosive esophagitis (LA Grade C and D)
    • EditedActivePresence of active Crohn's disease.
    • RemovedSevere psychiatric illness, dementia, active psychosis, history of suicide attempt, or alcohol/substance abuse within 12 months.
    • RemovedPregnant, breastfeeding, planning pregnancy, or not using adequate contraception.
    • RemovedMalignancy within the prior 12 months (except non-melanoma skin cancer).
    • RemovedLife expectancy < 2 years in investigator's judgment.
    • AddedPsychiatric disorders including (but not limited to) dementia, active psychosis, severe depression requiring 3 or more medications, history of suicide attempts, active alcohol, or substance abuse within the previous 12 months that in the opinion of the investigators could disqualify the patient from metabolic surgery
    • AddedPregnancy, the intention of becoming pregnant, or not using adequate contraceptive measures

    …and 25 more changes, on the record history on ClinicalTrials.gov ↗

    Contact Study contact changed: h•••@ccf.org · •••5022→d•••@ccf.org · •••0045; removed A•••@ccf.org. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cleveland Clinic Main Campus · Cleveland, United StatesContact h•••@ccf.org · •••5022→D•••@ccf.org · •••0045Contact A•••@ccf.org→none listedContact removed (no phone or email listed)Contact removed (no phone or email listed)
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07058155
Responsible party
Ali Aminian (MD, The Cleveland Clinic) — Principal investigator
First posted
Jul 10, 2025
Start date
Dec 17, 2025
Primary completion
Feb 1, 2029 (estimated)
Completion
Feb 1, 2034 (estimated)
Last update
Oct 22, 2026

Study contacts

Ghazal F Daftari, MD
Contact
daftarg@ccf.org
857-498-0045
Ali Aminian, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion